21 completed, 13 terminated, 1 unknown. 17 Phase 3, 16 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 10, Terminated 7 |
| Phase 2 | 16 | Completed 9, Terminated 6, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow tanezumab: new trials by email Literature Review of tanezumab trials Research Report on tanezumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis Tanezumab, Placebo - Schwannomatosis, Pain | Phase 2 | Unknown | Massachusetts General Hospital | 9 | 2020-04-30 | 2024-03-13 |
| Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain Celecoxib, Tanezumab 5 mg, Tanezumab 10 mg - Low Back Pain | Phase 3 | Completed | Pfizer | 277 | 2016-05-26 | 2020-08-11 |
| Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee. Tanezumab, Placebo - Osteoarthritis, Hip, Osteoarthritis, Knee | Phase 3 | Completed | Pfizer | 849 | 2016-03-02 | 2019-06-26 |
| Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 3 | Completed | Pfizer | 698 | 2016-01-21 | 2021-05-03 |
| Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy Tanezumab - Bone Metastasis, Cancer Pain | Phase 3 | Completed | Pfizer | 156 | 2015-10-28 | 2023-02-16 |
| A Phase 3 Study of Tanezumab for Chronic Low Back Pain Placebo to Week 16; tanezumab 5mg SC, Placebo to Week 16, tanezumab 10 mg SC, Tanezumab 5 mg SC - Low Back Pain | Phase 3 | Completed | Pfizer | 1832 | 2015-08-18 | 2020-02-21 |
| Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg - Chronic Pain, Osteoarthritis, Hip | Phase 3 | Completed | Pfizer | 3021 | 2015-07-21 | 2020-01-10 |
| Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis Tanezumab, Placebo - Chronic Pancreatitis | Phase 2 | Terminated | Pfizer | 2 | 2010-10-13 | 2021-03-23 |
| Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis Tanezumab - Osteoarthritis | Phase 3 | Terminated | Pfizer | 1 | 2010-06-15 | 2021-03-10 |
| A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy Tanezumab, placebo - Diabetic Peripheral Neuropathy | Phase 2 | Terminated | Pfizer | 73 | 2010-03-30 | 2021-02-24 |
| Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients Tanezumab, Placebo - Osteoarthritis | Phase 3 | Terminated | Pfizer | 21 | 2010-02-15 | 2021-02-08 |
| A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome Tanezumab, Placebo - Cystitis, Interstitial | Phase 2 | Terminated | Pfizer | 205 | 2010-01-22 | 2021-08-03 |
| Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected placebo, tanezumab - Osteoarthritis Pain, Chronic Low Back Pain | Phase 1 | Completed | Pfizer | 28 | 2009-12-01 | 2011-04-26 |
| A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg - Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 2 | Terminated | Pfizer | 679 | 2009-11-17 | 2021-05-13 |
| Tanezumab In Osteoarthritis Of The Hip Or Knee tanezumab 10 mg, tanezumab 5 mg, oxycodone - Osteoarthritis | Phase 3 | Terminated | Pfizer | 614 | 2009-10-30 | 2021-05-14 |
| Long Term Safety Study of Tanezumab in Chronic Low Back Pain Tanezumab 20 mg, Tanezumab 10 mg - Low Back Pain | Phase 2 | Terminated | Pfizer | 849 | 2009-08-20 | 2021-04-21 |
| Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip tanezumab, diclofenac, IV placebo - Osteoarthritis | Phase 3 | Terminated | Pfizer | 607 | 2009-08-11 | 2021-02-26 |
| A Study of Tanezumab in Adults With Chronic Low Back Pain Tanezumab 20 mg IV, Placebo for naproxen, Tanezumab 10 mg IV - Low Back Pain | Phase 2 | Completed | Pfizer | 1359 | 2009-06-15 | 2021-07-07 |
| Tanezumab in Osteoarthritis of the Hip or Knee (2) tanezumab 10 mg, tanezumab 5 mg, naproxen - Osteoarthritis | Phase 3 | Completed | Pfizer | 849 | 2009-06-09 | 2021-05-17 |
| Tanezumab and Nerve Function In Arthritis Patients tanezumab, Placebo - Osteoarthritis | Phase 3 | Terminated | Pfizer | 220 | 2009-05-18 | 2021-02-04 |
Showing 20 of 35. Sign in to see all of them.
Osteoarthritis (14) · Arthritis (7) · Hereditary Sensory and Autonomic Neuropathies (7) · Pain (6) · Low Back Pain (5) · Osteoarthritis, Hip (5) · Osteoarthritis, Knee (5) · Chronic Pain (3) · Cystitis, Interstitial (2) · Cancer Pain (1) · Diabetic Neuropathies (1) · Endometriosis (1) · Joint Diseases (1) · Multiple Myeloma (1) · Musculoskeletal Diseases (1)
Pfizer (34) · Massachusetts General Hospital (1)
United States (30) · Japan (7) · Spain (7) · Poland (6) · South Korea (6) · Sweden (6) · Austria (5) · Canada (5) · France (5) · Slovakia (5) · Hungary (4) · Romania (4) · Russia (4) · Germany (3) · Mexico (3)
Scott R Plotkin (1)
PMID 30936738, PMID 37460782, PMID 26554876, PMID 35232805, PMID 35960482, PMID 35980115, PMID 36301512, PMID 36474952, PMID 37470295, PMID 37652258, PMID 38343426, PMID 38650049, PMID 25274899, PMID 25594611, PMID 32734597, PMID 33973384, PMID 34626502, PMID 35105318, PMID 36621827, PMID 20942668, PMID 21251985, PMID 21941281, PMID 22004765, PMID 23553790, PMID 23628600, PMID 23707270, PMID 23852695, PMID 24625625, PMID 24937440, PMID 25073573, PMID 25919474, PMID 31265100, PMID 32234715, PMID 32252976, PMID 32453139, PMID 33538113, PMID 33728717, PMID 34786956, PMID 35217440, PMID 35351194, PMID 35962939, PMID 36038003, PMID 37343145, PMID 37982583
2008 (3), 2009 (3)